Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Day One Biopharmaceuticals Inc
NASDAQ DAWN
Data sourced from
and
and
Day One Biopharmaceuticals Inc Cash Interest Coverage Ratio for the quarter ending March 31, 2024
Day One Biopharmaceuticals Inc Cash Interest Coverage Ratio is NA for the quarter ending March 31, 2024. The cash interest coverage ratio measures a company's ability to cover its interest expenses with its operating cash flow. It is calculated by dividing operating cash flow by interest expense. This ratio indicates the company's capacity to generate sufficient cash flow to meet its interest obligations. A higher ratio signifies better coverage and financial stability.
-
Day One Biopharmaceuticals Inc Cash Interest Coverage Ratio for the quarter ending March 31, 2023 was -7.51, a 99.93% change year over year.
-
Day One Biopharmaceuticals Inc Cash Interest Coverage Ratio for the quarter ending March 31, 2022 was -10,781.50, a -674.61% change year over year.
-
Day One Biopharmaceuticals Inc Cash Interest Coverage Ratio for the quarter ending March 31, 2021 was -1,391.86, a -100.27% change year over year.
-
Day One Biopharmaceuticals Inc Cash Interest Coverage Ratio for the quarter ending March 31, 2020 was -695.00.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: DAWN
| CEO | Dr. Jeremy Bender M.B.A., Ph.D. |
| IPO Date | May 27, 2021 |
| Location | United States |
| Headquarters | 395 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 |
| Employees | 174 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Key trends
Similar companies
Acumen Pharmaceuticals Inc
NA
NA
Eledon Pharmaceuticals Inc
NA
NA
StockViz Staff
September 19, 2024
Any question? Send us an email